Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Live Cell Imaging Ready to Transform Disease Diagnostics and Drug Discovery

By BiotechDaily International staff writers
Posted on 31 Mar 2014
Breakthroughs in fluorescent applications, electronics, optics, and molecular biology have made live cell imaging technologies more accessible to life scientists trying to better understand biologic dynamics and visualize cellular events in living organisms, according to recent market research. The introduction of “omics” technologies and nanotechnologies into mainstream medicine has already enabled commercial lab-on-a-chip microfluidics systems that analyze cells, DNA, RNA, and proteins. As live cell imaging evolves, it will become a key player in disease diagnostics and drug discovery processes.

New analysis from Frost & Sullivan (Mountain View, CA, USA), an international growth consultancy company, found that live cell imaging technologies will have a large number of niche applications in cancer research, cell biology, developmental biology, and neuroscience. Currently available technologies include live cell-based tests systems and molecular models including high-resolution imaging systems.

“The principal challenges to successful live cell imaging are microscopic settings optimization, fluorescent components selection, and culture environment maintenance,” said technical insights senior research analyst Cecilia Van Cauwenberghe. “Parallel advances in the field of cell culturing will also be critical to ensure accurate, real-time results.”

Utilizing live cell imaging along with fixed cell tests before the former totally replaces the latter, will lower costs and lessen throughput times. Equipment combining microscopes with cell culture incubators is already being marketed, facilitating affordable three-dimensional (3D), real-time assessment, multiplexing, and automation capabilities.

Tightly integrated systems can provide new benchmarks of precision and degrees of efficiency for the study of individual and small groups of live cells. They will enable innovative new ways for multiple cell analysis, simultaneous processing, and multi-day time lapse live cell imaging. However, it is essential that government patent systems protect these innovations, especially since new players in the market emerge from different start points. Similarly, measures must be taken to reduce uncertainty regarding reimbursements, and to establish frameworks assuring balance among tier I companies, small and medium enterprises, and start-ups developing innovative technologies.

“Intellectual property regimes promoting integration between academia and industry in order to deliver new solutions are necessary,” concluded Ms. Cauwenberghe. “Drug producers must collaborate with other stakeholders to translate live cell imaging innovations into clinically meaningful tests that can be used for diagnosis, prognosis and drug development.”

Related Links:

Frost & Sullivan



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.